Cargando…
Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach
BACKGROUND: The determinants of access to immunizers are still poorly understood, leading to questions about which criteria were considered in this distribution. Given the above, the present study aimed to analyze the determinants of access to the SARS-CoV-2 vaccine by different countries. METHODS:...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363862/ https://www.ncbi.nlm.nih.gov/pubmed/34391416 http://dx.doi.org/10.1186/s12939-021-01520-4 |
_version_ | 1783738424114544640 |
---|---|
author | de Oliveira, Brigitte Renata Bezerra da Penha Sobral, Ana Iza Gomes Marinho, Marcelo Luiz Monteiro Sobral, Marcos Felipe Falcão de Souza Melo, André Duarte, Gisleia Benini |
author_facet | de Oliveira, Brigitte Renata Bezerra da Penha Sobral, Ana Iza Gomes Marinho, Marcelo Luiz Monteiro Sobral, Marcos Felipe Falcão de Souza Melo, André Duarte, Gisleia Benini |
author_sort | de Oliveira, Brigitte Renata Bezerra |
collection | PubMed |
description | BACKGROUND: The determinants of access to immunizers are still poorly understood, leading to questions about which criteria were considered in this distribution. Given the above, the present study aimed to analyze the determinants of access to the SARS-CoV-2 vaccine by different countries. METHODS: The study covered 189 countries using data from different public databases, and collected until February 19, 2021. We used eight explanatory variables: gross domestic product (GDP), extreme poverty, human development index (HDI), life expectancy, median age, coronavirus disease 2019 (COVID-19) cases, COVID-19 tests, and COVID-19 deaths. The endogenous variables were total vaccine doses, vaccine doses per thousand, and days of vaccination. The structural equation modeling (SEM) technique was applied to establish the causal relationship between the country's COVID-19 impact, socioeconomic variables, and vaccine access. To support SEM, we used confirmatory factor analysis, t-test, and Pearson's correlation. RESULTS: We collected the sample on February 19, and to date, 80 countries (42.1%) had already received a batch of immunizers against COVID-19. The countries with first access to the vaccine (e.g., number of days elapsed since they took the first dose) were the United Kingdom (68), China (68), Russia (66), and Israel (62). The countries receiving the highest doses were the United States, China, India, and Israel. The countries with extreme poverty had lower access to vaccines and the richer countries gained priority access. Countries most affected by COVID (deaths and cases) also received immunizers earlier and in greater volumes. Unfortunately, similar to other vaccines, indicators, such as income, poverty, and human development, influence vaccines' access. Thus affecting the population of vulnerable and less protected countries. Therefore, global initiatives for the equitable distribution of COVID need to be discussed and encouraged. CONCLUSIONS: Determinants of vaccine distribution consider the impact of the disease in the country and are also affected by favorable socioeconomic indicators. The COVID-19 vaccines need to be accessible to all affected countries, regardless of their social hands. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12939-021-01520-4. |
format | Online Article Text |
id | pubmed-8363862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83638622021-08-15 Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach de Oliveira, Brigitte Renata Bezerra da Penha Sobral, Ana Iza Gomes Marinho, Marcelo Luiz Monteiro Sobral, Marcos Felipe Falcão de Souza Melo, André Duarte, Gisleia Benini Int J Equity Health Research BACKGROUND: The determinants of access to immunizers are still poorly understood, leading to questions about which criteria were considered in this distribution. Given the above, the present study aimed to analyze the determinants of access to the SARS-CoV-2 vaccine by different countries. METHODS: The study covered 189 countries using data from different public databases, and collected until February 19, 2021. We used eight explanatory variables: gross domestic product (GDP), extreme poverty, human development index (HDI), life expectancy, median age, coronavirus disease 2019 (COVID-19) cases, COVID-19 tests, and COVID-19 deaths. The endogenous variables were total vaccine doses, vaccine doses per thousand, and days of vaccination. The structural equation modeling (SEM) technique was applied to establish the causal relationship between the country's COVID-19 impact, socioeconomic variables, and vaccine access. To support SEM, we used confirmatory factor analysis, t-test, and Pearson's correlation. RESULTS: We collected the sample on February 19, and to date, 80 countries (42.1%) had already received a batch of immunizers against COVID-19. The countries with first access to the vaccine (e.g., number of days elapsed since they took the first dose) were the United Kingdom (68), China (68), Russia (66), and Israel (62). The countries receiving the highest doses were the United States, China, India, and Israel. The countries with extreme poverty had lower access to vaccines and the richer countries gained priority access. Countries most affected by COVID (deaths and cases) also received immunizers earlier and in greater volumes. Unfortunately, similar to other vaccines, indicators, such as income, poverty, and human development, influence vaccines' access. Thus affecting the population of vulnerable and less protected countries. Therefore, global initiatives for the equitable distribution of COVID need to be discussed and encouraged. CONCLUSIONS: Determinants of vaccine distribution consider the impact of the disease in the country and are also affected by favorable socioeconomic indicators. The COVID-19 vaccines need to be accessible to all affected countries, regardless of their social hands. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12939-021-01520-4. BioMed Central 2021-08-14 /pmc/articles/PMC8363862/ /pubmed/34391416 http://dx.doi.org/10.1186/s12939-021-01520-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research de Oliveira, Brigitte Renata Bezerra da Penha Sobral, Ana Iza Gomes Marinho, Marcelo Luiz Monteiro Sobral, Marcos Felipe Falcão de Souza Melo, André Duarte, Gisleia Benini Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach |
title | Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach |
title_full | Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach |
title_fullStr | Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach |
title_full_unstemmed | Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach |
title_short | Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach |
title_sort | determinants of access to the sars-cov-2 vaccine: a preliminary approach |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363862/ https://www.ncbi.nlm.nih.gov/pubmed/34391416 http://dx.doi.org/10.1186/s12939-021-01520-4 |
work_keys_str_mv | AT deoliveirabrigitterenatabezerra determinantsofaccesstothesarscov2vaccineapreliminaryapproach AT dapenhasobralanaizagomes determinantsofaccesstothesarscov2vaccineapreliminaryapproach AT marinhomarceloluizmonteiro determinantsofaccesstothesarscov2vaccineapreliminaryapproach AT sobralmarcosfelipefalcao determinantsofaccesstothesarscov2vaccineapreliminaryapproach AT desouzameloandre determinantsofaccesstothesarscov2vaccineapreliminaryapproach AT duartegisleiabenini determinantsofaccesstothesarscov2vaccineapreliminaryapproach |